Lilly eloraTZP at EASD: what would the Phase 2 result actually establish?
Keep the announced presentation schedule and the registered study side by side. Use the same source checklist when reading a later results release.
Company claims are attributed to the dated sources below. ORION’s editorial checklist is explained in Coverage & method.
01 / SOURCE RECORD
What is confirmed
- Lilly announced that a 30 September 2026 EASD symposium will feature Phase 2 results for eloraTZP, the investigational eloralintide and tirzepatide combination, in adults with obesity or overweight and type 2 diabetes.
- Lilly’s study page identifies NCT06603571 as a Phase 2 study of eloralintide alone or with tirzepatide. The study listing is not a results disclosure.
Verify these points in the linked primary sources. Source language and numbers may be updated later; this page captures the dated release.
02 / INTERPRETATION
How we read the change
Read any reported effect alongside its dose, comparator, treatment duration and tolerability. Those details define the comparison to make with the original study record.
What would change our view?
Compare the combination and single-agent regimens at the reported dose and follow-up, including adverse events and discontinuations.
03 / NEXT CHECK
Questions to revisit
- How much benefit does the combination add over the relevant single-agent regimen, at what dose and follow-up?
- How do adverse events, discontinuations and missing data affect the comparison?
- Does Lilly describe a confirmatory program, or only this Phase 2 readout?
04 / EVIDENCE
Open the primary sources
Source review date: 2026-09-23. Open the complete issuer and registry materials at their original URLs.